Genmab AS (LTS:0MGB) Cyclically Adjusted Book per Share: kr351.30 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0MGB Genmab AS LTS:0MGB
97 GF Score
Price kr2,029.25
GF Value kr2,289.21
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Genmab AS Cyclically Adjusted Book per Share?

Genmab AS LTS:0MGB +1.18% 97 Cyclically Adjusted Book per Share is kr351.30 as of Jun. 2026. GuruFocus rates LTS:0MGB with a GF Score™ of 97/100 and a GF Value™ of kr2,289.21 (Modestly Undervalued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Genmab AS's adjusted book value per share for the three months ended in Jun. 2026 was kr629.296. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is kr351.30 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Genmab AS's average Cyclically Adjusted Book Growth Rate was 20.40% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 24.60% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 30.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Genmab AS was 40.30% per year. The lowest was 24.60% per year. And the median was 33.25% per year.

As of today (2026-08-16), Genmab AS's current stock price is kr2029.25. Genmab AS's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 was kr351.30. Genmab AS's Cyclically Adjusted PB Ratio of today is 5.78.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Genmab AS was 39.38. The lowest was 4.40. And the median was 20.57.


Genmab AS  (LTS:0MGB) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Genmab AS's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=2029.25/351.30
=5.78

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Genmab AS was 39.38. The lowest was 4.40. And the median was 20.57.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Genmab AS Cyclically Adjusted Book per Share Related Terms


Genmab AS Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Genmab AS's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genmab AS Cyclically Adjusted Book per Share Chart

Genmab AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 116.77 166.92 209.67 264.62 319.92

Genmab AS Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 292.26 307.54 319.92 334.56 351.30

LTS:0MGB vs VRTX, REGN, RVMD: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Genmab AS's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genmab AS Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genmab AS's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Genmab AS's Cyclically Adjusted PB Ratio falls into.


LTS:0MGB
97GF Score
Genmab AS LTS:0MGB
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genmab AS Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Genmab AS's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book= Book Value per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=629.296/122.9700*122.9700
=629.296

Current CPI (Jun. 2026) = 122.9700.

Genmab AS Quarterly Data

Book Value per Share CPI Adj_Book
201609 65.352 100.200 80.203
201612 79.944 100.300 98.013
201703 82.491 101.200 100.236
201706 90.784 101.200 110.313
201709 88.502 101.800 106.907
201712 104.053 101.300 126.312
201803 106.472 101.700 128.740
201806 110.815 102.300 133.205
201809 114.862 102.400 137.935
201812 131.293 102.100 158.130
201903 131.206 102.900 156.797
201906 135.672 102.900 162.134
201909 191.279 102.900 228.587
201912 218.131 102.900 260.676
202003 221.135 103.300 263.243
202006 273.865 103.200 326.329
202009 281.591 103.500 334.563
202012 295.459 103.400 351.379
202103 302.680 104.300 356.861
202106 304.858 105.000 357.032
202109 321.000 105.800 373.094
202112 338.376 106.600 390.339
202203 350.217 109.900 391.867
202206 368.046 113.600 398.403
202209 402.326 116.400 425.035
202212 421.840 115.900 447.573
202303 424.249 117.300 444.756
202306 441.697 116.400 466.628
202309 471.413 117.400 493.779
202312 490.352 116.700 516.697
202403 495.032 118.400 514.139
202406 485.686 118.500 504.007
202409 505.732 118.900 523.043
202412 575.798 118.900 595.508
202503 576.839 120.200 590.132
202506 557.588 120.700 568.075
202509 593.997 121.600 600.689
202512 605.440 121.200 614.282
202603 598.391 121.680 604.735
202606 629.296 122.970 629.296

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of kr351.30 mean?
Genmab AS (LTS:0MGB) has a Cyclically Adjusted Book per Share of kr351.30 as of Jun. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Genmab AS and its competitors.
Is Genmab AS's Cyclically Adjusted Book per Share too high?
Genmab AS's current Cyclically Adjusted Book per Share is kr351.30. Overall, Genmab AS has a GF Score™ of 97/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genmab AS's Cyclically Adjusted Book per Share compare to VRTX and REGN?
Genmab AS's Cyclically Adjusted Book per Share of kr351.30 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Genmab AS and its competitors. Genmab AS's current Cyclically Adjusted Book per Share is kr351.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genmab AS stock overvalued right now?
Based on GuruFocus' analysis, Genmab AS (LTS:0MGB) is currently considered Modestly Undervalued. The stock's GF Value™ is kr2,289.21, compared to a current price of kr2,029.25 — trading 11.4% below its estimated fair value. The current Cyclically Adjusted Book per Share is kr351.30. Genmab AS's overall GF Score™ is 97/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Genmab AS (LTS:0MGB), the current Cyclically Adjusted Book per Share is kr351.30 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Genmab AS (LTS:0MGB) Overvalued in 2026?

Based on GuruFocus' analysis, Genmab AS stock appears to be undervalued. The current stock price of kr2,029.25 is trading 11.4% below its estimated GF Value™ of kr2,289.21. GuruFocus considers Genmab AS to be Modestly Undervalued.

Key valuation signals for LTS:0MGB:

  • Cyclically Adjusted Book per Share: kr351.30
  • GF Value™: kr2,289.21 vs. price of kr2,029.25 (11.4% below fair value)
  • GF Score™: 97/100 with 5 warning signs

No single metric tells the full story. See the LTS:0MGB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Genmab AS Business Description

Address Carl Jacobsens Vej 30, Valby, DNK, 2500
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
97GF Score

Get the complete analysis for LTS:0MGB

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr2,029.25
Price
kr2,289.21
GF Value